Flowserve Corporation Common Stock vs Oruka Therapeutics Inc. Common Stock — how do they compare? Flowserve Corporation Common Stock trades at $69.98 (market cap $9.08B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Flowserve Corporation Common Stock is the larger of the two by market cap, and Flowserve Corporation Common Stock pays a 1.23% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flowserve Corporation Common Stock for 6 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| FLS | ORKA | |
|---|---|---|
Market Cap | $9.08B | $5.18B |
Volume | 1,742,251 | 490,798 |
Sector | Industrials | Health |
52-Week High | $92.04 | $113.08 |
52-Week Low | $50.41 | $26.19 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.67B | $4.31B |
Dividend Yield | 1.23% | — |
Signals from Pluang's Aura AI — not financial advice
FLS trades at $71.47, up 1.16% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Revenue for 2025 was $4.73 billion, with a net income margin of 8.01%. Recent news includes a new CFO appointment and a quarterly dividend declaration.
The outlook is mixed: strong fundamentals and a consensus price target of $90.75 suggest upside, but technical weakness and a high P/E of 24.9 pose risks. Key opportunities include strategic acquisitions and nuclear market exposure, while headwinds include weak organic sales and rising debt levels noted by analysts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Flowserve Corporation is a Texas-based manufacturer of engineered flow-control equipment, producing industrial pumps, mechanical seals, valves, and automation products through its Flowserve Pumps Division and Flow Control Division, serving the oil and gas, chemical, power, and water industries in more than 50 countries.
Read more on FLS →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →